MILYNVO
LIVE

Serial Number

98371993

Owner

Laminar Pharmaceuticals S. A.

Attorney

Gerald E. Hespos

Filing Date

Jan 23, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MILYNVO Trademark

Serial Number: 98371993 • Registration: 7798312

MILYNVO is a trademark filed by Laminar Pharmaceuticals S. A. on January 23, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Laminar Pharmaceuticals S. A.

Ctra. de Valldemossa Km. 7.4, ParcBIT, t
Palma de Mallorca (Isl E-07121 , ES

Entity Type: 03

Trademark Details

Filing Date

January 23, 2024

Registration Date

May 20, 2025

Published for Opposition

April 1, 2025

Goods & Services

Pharmaceutical compositions, namely, preparations for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Pharmaceutical drugs, namely, preparations for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Medicines for human purposes for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Medicines for veterinary purposes for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Pomades for medical purposes; Skin care preparations for medical use; Pharmaceutical preparations for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Herbal preparations for medical use; Nutraceutical preparations for therapeutic or medical purposes; Medicinal preparations and diagnostic substances for medical purposes; Pharmaceutical preparations and diagnostic substances for medical purposes; Veterinary preparations and diagnostic substances for medical purposes; Dietary supplements and dietetic preparations adapted for medical purposes; Natural remedies preparations for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Greases for medical or veterinary purposes; Animal fodder additives in the nature of acidifiers and enzymes for medical purposes; Additives in the nature of dietary supplements for animals; Dietary supplements for animals; Dietary supplements for human beings; Cardiovascular agents for medical purposes; Cellular function activating agents for medical purposes; Cachets for medicinal purposes, namely, antivirals and capsules for pharmaceutical purposes; Biological preparations for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Bacteriological preparations for medical and veterinary use; Biochemical preparations for medical use, namely, bioengineered membranes for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Biochemical preparations for veterinary use, namely, bioengineered membranes for the treatment of cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Biological reagents for medical use; Clinical medical reagents; Medical diagnostic reagents for the analysis of body fluids; Reagents for veterinary purposes for the analysis of body fluids; Diagnostic reagents for medical or veterinary purposes; Medical diagnostic reactants for medical diagnosis of disease; Reagents for use in diagnostic tests for medical purposes; Pharmaceutical compounds for treating cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmacological preparations for skincare; Pharmaceutical preparations for the treatment of disorders of the metabolic system; Pharmaceutical preparations for the treatment of diseases of the nervous system; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical agents for treating physically caused lesions; Probiotic, vitamin and mineral preparations in powder form, for medical use; Diagnostic and analytical kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis, for medical use or for veterinary purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of human and animal bodily fluids for medical purposes or for veterinary purposes; Diagnostic and analytical kits comprising diagnostic agents, preparations and substances for medical use; Diagnostic kits comprised primarily of medical diagnostic reagents, for medical use; Diagnostic kits comprised primarily of chemical reagent preparations for medical or veterinary use; Diagnostic test kits for medical diagnosis purposes consisting primarily of reagents for use in detecting diseases in humans and animals.

Applicators for medications, namely, syringes, nebulizers, spoons for administering medicine and medicinal catheters; Receptacles for applying medicines, namely, powder and liquid mixer cups for dispensing medicine, dosage dispensers for administering medicine to patients, dropper bottles for administering medication, sold empty and medicine dispensing kit comprised primarily of powder and liquid mixer cups for dispensing medicine and a dosage dispenser for administering medicine to patients; Injection devices for pharmaceuticals; Drug delivery devices sold empty, namely, syringes and infusion sets; Diagnostic apparatus for medical purposes used in medical laboratories for testing blood sugar levels, cancer cells, DNA, RNA, and body fluids; tools for medical diagnostics, namely, medical diagnostic instruments for testing blood sugar levels, cancer cells, DNA, RNA, and body fluids; Medical diagnostic apparatus for measuring blood sugar levels, cancer cells, DNA, RNA, and body fluids; Diagnostic apparatus for use in medical procedures for testing blood sugar levels, cancer cells, DNA, RNA, and body fluids; Testing apparatus for medical purposes; Test probe assemblies for medical use; Test probes for medical use; Testing instruments for medical diagnostic purposes, namely, for blood sugar levels, cancer cells, DNA, RNA, and body fluids; Testing probes for medical diagnostic purposes, namely, probes for cancer, vascular pathologies, obesity, hypertension, cutaneous pathologies, metabolic pathologies, cardiovascular diseases, inflammatory diseases, systemic diseases, respiratory diseases, infectious pathologies, nerve fibre lesions, neurodegenerative pathologies, including Alzheimer, neuroregeneration, neurological diseases, neuropathic pain, paralysis, sleep disorders, digestive pathologies, musculoskeletal and connective tissue diseases, genitourinary pathologies, hypercholesterolemia, hypertriglyceridemia and cystic fibrosis; Medical and diagnostic medical instrument kits for medical diagnosis purposes consisting primarily of probes, buffers and reagents for use in microbial testing.

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 20, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
May 20, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 1, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 1, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 10, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 15, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 3, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 3, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 3, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 19, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 24, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 24, 2024 NWOS
NEW APPLICATION ENTERED
Jan 23, 2024 NWAP